Benzinga | Oct 29, 2020 07:14AM EDT

Protalix BioTherapeutics Q3 EPS $(0.14) Beats $(0.17) Estimate, Sales $10.79M Beat $10.08M Estimate

Protalix BioTherapeutics (AMEX:PLX) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.17) by 17.65 percent. This is a 600 percent decrease over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $10.79 million which beat the analyst consensus estimate of $10.08 million by 7.04 percent. This is a 24.27 percent decrease over sales of $14.25 million the same period last year.